Analysts Offer Predictions for Aethlon Medical Q1 Earnings

Aethlon Medical, Inc. (NASDAQ:AEMD) – Stock analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Aethlon Medical in a report released on Thursday, August 14th. HC Wainwright analyst V. Bernardino expects that the medical equipment provider will earn ($0.14) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Aethlon Medical’s current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Aethlon Medical’s Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.14) EPS, FY2027 earnings at ($0.57) EPS, FY2028 earnings at ($0.49) EPS, FY2029 earnings at ($0.49) EPS and FY2030 earnings at ($0.33) EPS.

Aethlon Medical (NASDAQ:AEMD) last released its earnings results on Wednesday, August 13th. The medical equipment provider reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.17).

Separately, Wall Street Zen started coverage on Aethlon Medical in a research note on Thursday, May 15th. They issued a “sell” rating on the stock.

Aethlon Medical Trading Down 2.6%

NASDAQ:AEMD opened at $1.14 on Friday. Aethlon Medical has a 1-year low of $1.09 and a 1-year high of $8.44. The business’s 50-day moving average price is $1.40 and its two-hundred day moving average price is $2.81. The firm has a market capitalization of $2.96 million, a price-to-earnings ratio of -0.09 and a beta of 1.72.

Institutional Investors Weigh In On Aethlon Medical

Several large investors have recently modified their holdings of the business. Renaissance Technologies LLC bought a new stake in shares of Aethlon Medical in the fourth quarter worth about $25,000. Sassicaia Capital Advisers LLC bought a new stake in shares of Aethlon Medical in the fourth quarter worth about $31,000. Boothbay Fund Management LLC bought a new stake in shares of Aethlon Medical in the fourth quarter worth about $186,000. Finally, Armistice Capital LLC bought a new stake in shares of Aethlon Medical in the first quarter worth about $511,000. 1.99% of the stock is currently owned by institutional investors.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.